Impact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancer

Familial Cancer · Published 2026-07-22 · DOI 10.1007/s10689-026-00590-z

Authors (5)

Emma A. Kell, Michael P. Mullane, Jennifer L. Geurts, Brenda Ramczyk, Tessa M. Bachinski

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Kell, E., Mullane, M., Geurts, J., et al. (2026). Impact of updated NCCN guidelines on clinical management and risk communication for CHEK2 p.I157T carriers in breast cancer. Familial Cancer. https://doi.org/10.1007/s10689-026-00590-z

Related articles

• Colonoscopy findings and polyp pathology in CHEK2 carriers: a single center experience · Familial Cancer · 2026 · Same journal
• Familial risks in prostate cancer between brothers and half-brothers as clues to germline genetic and environmental causes · Familial Cancer · 2026 · Same journal
• Attenuated Li–Fraumeni syndrome with TP53 p.R181H in a Japanese patient with metastatic rectal adenocarcinoma: a case report · Familial Cancer · 2026 · Same journal
• Patient-derived outcome assessment of knowledge, communication, and management in those diagnosed with BAP1-tumor predisposition syndrome · Familial Cancer · 2026 · Same journal
• Breast cancer phenotypes in carriers of pathogenic POT1 variants · Familial Cancer · 2026 · Same journal
• Homozygous TP53 alterations: a case of a biallelic splice variant and a brief review of the literature · Familial Cancer · 2026 · Same journal
• Genotypic and phenotypic characteristics of germline TP53 variant carriers: experience from two cancer genetic counseling units · Familial Cancer · 2026 · Same journal
• When screentime fails: initiative to improve completion of hereditary cancer genetic testing after telemedicine counseling · Familial Cancer · 2026 · Same journal
• Trends in breast reconstruction for BRCA1/2, PALB2 and other high penetrance germline pathogenic variant carriers undergoing risk reducing mastectomy · Familial Cancer · 2026 · Same journal
• Biallelic germline MBD4 mutations predispose to colorectal polyposis, hypermutated AML, and schwannomas · Familial Cancer · 2026 · Same journal